|
Aclarion Inc (NASDAQ: ACON) |
|
Aclarion Inc
ACON's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Aclarion Inc 's sales fell
by -25.84 % in the fourth quarter of 2024 from the same quarter a year ago.
Ranking at No. 2832
Medical Laboratories industry recorded
growth of revenues by 6.22 %
Aclarion Inc net loss increased from $-1 millions, to $-2 millions in fourth quarter of 2024,
• More on ACON's Growth
|
|
Aclarion Inc realized a net loss in trailing twelve months.
Aclarion Inc realized cash reduction of $ -601.79 per share in trailing twelve-month period. |
Company |
-0 |
PE TTM
|
Industry |
-0 |
PE TTM
|
|
Company's Price to Sales ratio is at 0.15.
Medical Laboratories industry's Price to Sales ratio is at 2.18.
• More on ACON's Valuation
|
|
|
|
|
Aclarion Inc realized net loss in trailing twelve months.
Aclarion Inc realized cash outflow of $ -601.79per share in trailing twelve-month period. |
Company |
-0 |
PE TTM
|
Industry |
-0 |
PE TTM
|
|
Company's Price to Sales ratio is at 0.15.
Medical Laboratories industry's Price to Sales ratio is at 2.18.
Aclarion Inc Price to Book Ratio is at 0.01 lower than Industry Avg. of 148.13. and equal to S&P 500 Avg. of 0.01
• More on ACON's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com